Larimar Therapeutics Inc - Asset Resilience Ratio
Larimar Therapeutics Inc (LRMR) has an Asset Resilience Ratio of 38.46% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Larimar Therapeutics Inc (LRMR) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Larimar Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Larimar Therapeutics Inc asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Larimar Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of Larimar Therapeutics Inc to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $63.58 Million | 38.46% |
| Total Liquid Assets | $63.58 Million | 38.46% |
Asset Resilience Insights
- Very High Liquidity: Larimar Therapeutics Inc maintains exceptional liquid asset reserves at 38.46% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Larimar Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Larimar Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Larimar Therapeutics Inc (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Larimar Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 35.27% | $51.44 Million | $145.84 Million | -39.76pp |
| 2024-12-31 | 75.03% | $150.24 Million | $200.22 Million | +12.45pp |
| 2023-12-31 | 62.59% | $60.04 Million | $95.94 Million | -9.88pp |
| 2022-12-31 | 72.47% | $91.60 Million | $126.41 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $78.67 Million | -- |
| 2020-12-31 | 23.39% | $24.49 Million | $104.69 Million | -33.06pp |
| 2018-12-31 | 56.45% | $68.73 Million | $121.76 Million | -1.62pp |
| 2017-12-31 | 58.08% | $61.27 Million | $105.51 Million | -15.50pp |
| 2016-12-31 | 73.58% | $96.84 Million | $131.62 Million | -5.47pp |
| 2015-12-31 | 79.05% | $149.48 Million | $189.11 Million | +30.24pp |
| 2014-12-31 | 48.81% | $57.36 Million | $117.52 Million | -- |
About Larimar Therapeutics Inc
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.